Kaitlyn Arsenault - 04 Oct 2021 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Financial Officer
Signature
Kaitlyn Arsenault
Issuer symbol
SKYE
Transactions as of
04 Oct 2021
Net transactions value
$0
Form type
4
Filing time
05 Oct 2021, 20:42:51 UTC
Next filing
16 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Employee Stock Option (Right to Buy) Award $0 +1,600,000 +400% $0.000000 2,000,000 04 Oct 2021 Common Stock 1,600,000 $0.0900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 10% of the Options shall vest on October 4, 2021 (the "Vesting Start Date") and the remaining 90% of the Options will vest in equal semi-annual installments over four annual periods.